LY4065967 + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Peripheral Neuropathic Pain
Conditions
Diabetic Peripheral Neuropathic Pain
Trial Timeline
Feb 16, 2026 → Jul 1, 2027
NCT ID
NCT07285018About LY4065967 + Placebo
LY4065967 + Placebo is a phase 2 stage product being developed by Eli Lilly for Diabetic Peripheral Neuropathic Pain. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07285018. Target conditions include Diabetic Peripheral Neuropathic Pain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07285018 | Phase 2 | Recruiting |
Competing Products
20 competing products in Diabetic Peripheral Neuropathic Pain